| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Enovis Corporation$21.87
-0.14 (-0.64%)
Market Cap
1.39 B
EPS
-19.86
P/E Ratio
-
Value Trade
22.51 M
SEC Financials
Q2 2026Dilution Risk
Revenue
589.15 M
R&D Expenses
31.53 M
Operating CF
23.95 M
Total Assets
3.83 B
Total Liabilities
2.35 B
Equity
1.48 B
D/E Ratio
12,345
-6.57 %
Week
0.75 %
1 Month
8.87 %
3 Month
-10.44 %
6 Month
-68.19 %
5 Year
-37.49 %
All Time
Cash Data
Cash Position
33.13 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
230.12 K
52 Week Range
21 - 36.82
% held by Insiders
2.44 %
% held by Institutions
117.13 %
Enterprise Value
2.77 B
Total Shares
57.30 M
Short %
16.11 %
Float Shares
55.64 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ENOV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ENOV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ENOV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ENOV
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ENOV Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ENOV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ENOVEnovis Launches Spinamic Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
Enovis Corporation has launched the DonJoy Spinamic Hybrid Scoliosis Brace, designed to merge the corrective capabilities of traditional rigid braces with the comfort of dynamic options. The brace can be fitted in 10 sizes and utilizes an adjustable three-point pressure system to enhance wearability and compliance among adolescents with adolescent idiopathic scoliosis (AIS). Currently available in the U.S., the Spinamic brace aims to improve treatment outcomes while reducing the psychological burden often associated with traditional bracing methods. Enovis is also seeking regulatory clearance in additional markets worldwide.
Read more →ENOVEnovis Announces First Quarter 2026 Results
Enovis Corporation reported a 5% increase in first-quarter sales for 2026, driven by an 11% growth in Reconstructive sales. Despite a net loss of $8 million, the company reaffirmed its full-year financial guidance, highlighting confidence in its innovation-led strategy. The results reflect stable market conditions and successful new product introductions.
Read more →ENOVEnovis to Host First Quarter 2026 Results Conference Call on May 7th
Enovis Corporation will hold a conference call on May 7, 2026, to discuss its first quarter financial results. The call will be accessible via a live webcast and will include an earnings press release. Investors can participate by dialing in or accessing the webcast through the company's website.
Read more →ENOVUpdate: Enovis Announces Fourth Quarter and Full Year 2025 Results
Enovis Corporation reported its financial results for Q4 and full year 2025, showing a 3% increase in Q4 net sales and a 7% increase for the full year. However, the company faced a substantial net loss of $1,182 million, largely due to a goodwill impairment charge. Looking ahead, Enovis expects revenue growth of 4-6% for 2026, with adjusted EBITDA projected between $425-435 million.
Read more →ENOVEnovis Announces Fourth Quarter and Full Year 2025 Results
Enovis Corporation reported its financial results for Q4 and full year 2025, showing a 3% increase in net sales for Q4 and a 7% increase for the full year. However, the company faced a substantial net loss of $519 million in Q4 due to a goodwill impairment charge. Looking ahead, Enovis expects revenue growth of 4-6% for 2026, with adjusted EBITDA projected between $425-435 million.
Read more →ENOVEnovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Enovis Corporation will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. The event will take place in Snowbird, Utah, showcasing Enovis's commitment to innovation in medical technology. The company focuses on developing solutions that improve patient outcomes and enhance surgical efficiency.
Read more →ENOVEnovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th
Enovis Corporation will host an investor conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will start at 8:30 a.m. Eastern Time, with an earnings press release issued earlier that day. Investors can access the live webcast through the Enovis website.
Read more →ENOVEnovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Enovis Corporation (NYSE: ENOV) has announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will occur at 4:30 p.m. PST and will be accessible via a live audio webcast. Enovis is known for creating clinically differentiated medical solutions aimed at enhancing patient lives. The company emphasizes transparency by routinely sharing material information through various channels, including its Investor Relations website.
Read more →ENOVEnovis Appoints Oliver Engert as Chief Administrative Officer
Enovis Corporation has appointed Oliver Engert as Chief Administrative Officer, effective immediately. In this newly created role, Engert will focus on strategy development and operational efficiency to support the company's growth. CEO Damien McDonald expressed confidence in Engert's ability to drive success and improve patient care through his extensive experience.
Read more →ENOVEnovis Announces Third Quarter 2025 Results
Enovis Corporation reported its third-quarter financial results for 2025, showcasing a 9% increase in net sales year-over-year, reaching $549 million. Despite this growth, the company faced a substantial net loss of $571 million, primarily due to a non-cash goodwill impairment charge. The CEO emphasized a focus on strategic priorities for future growth, including operational excellence and innovation.
Read more →ENOVEnovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences
Enovis Corporation announced it will host a conference call and live webcast on November 6, 2025, to discuss its third quarter financial results. The company will also participate in various investor conferences. Investors can access the webcast and a replay on Enovis' website, enhancing transparency and communication.
Read more →ENOVEnovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
Enovis Corporation has completed the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners for up to $60 million. The transaction includes an upfront payment of $45 million, with additional payments contingent on future milestones. This divestiture is aimed at enhancing Enovis's focus on its core medical technology strengths and improving profitability.
Read more →ENOVEnovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
Enovis Corporation has announced a time change for its presentation at the Baird 2025 Global Healthcare Conference, now scheduled for 2:35 p.m. ET on September 10, 2025. The company emphasizes its commitment to innovation in medical technology and improving patient outcomes. A live audio webcast of the presentation will be accessible on their website.
Read more →ENOVEnovis to Participate in Upcoming Investor Conferences
Enovis Corporation announced its participation in upcoming investor conferences, showcasing its commitment to engaging with investors. The company emphasizes its focus on innovation in medical technology aimed at improving patient outcomes. Live audio webcasts of the events will be accessible on their website.
Read more →ENOVEnovis Announces Second Quarter 2025 Results
Enovis Corporation announced its financial results for the second quarter of 2025, reporting net sales of $565 million, which represents a growth of 7% year-over-year. The company's Reconstructive sales specifically grew by 11%, reflecting solid performance amidst stable end markets. Despite this growth, Enovis posted a net loss of $37 million and a loss per share of $0.64. The company also updated its 2025 revenue guidance, increasing it to between $2.245 billion and $2.275 billion.
Read more →ENOVEnovis to Host Second Quarter 2025 Results Conference Call on August 7th
Enovis Corporation has announced a conference call scheduled for August 7th, 2025, to discuss its second quarter financial results. The call will be accessible via a live webcast on the company's website, and a replay will be available afterward. This event highlights Enovis's commitment to transparency and investor communication.
Read more →ENOVEnovis Announces First Quarter 2025 Results
Enovis Corporation (NYSE: ENOV) reported an 8% increase in first-quarter sales, with significant growth in Reconstructive sales of 11% year-over-year. The company experienced an adjusted EBITDA margin expansion, despite reporting a net loss of $56 million. CEO Matt Trerotola emphasized strategic investment and disciplined execution for future growth. However, Enovis also revised its 2025 financial outlook downwards, factoring in a $20 million tariff-related impact.
Read more →ENOVEnovis to Host First Quarter 2025 Results Conference Call on May 8th
Enovis Corporation will host a conference call on May 8, 2025, to discuss its first quarter financial results. The call is scheduled for 8:30 a.m. Eastern Time, with an earnings press release to be issued earlier that morning. Investors can access the live webcast and participate via phone using the provided information. Enovis emphasizes its commitment to innovation and improving patient outcomes through its range of medical technology products.
Read more →ENOVEnovis Announces Appointment of Damien McDonald as Chief Executive Officer Damien McDonald appointed CEO, effective as of
Enovis Corporation has appointed Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. Mr. McDonald succeeds Matt Trerotola, who is retiring from the position and will not seek re-election at the upcoming Annual Meeting. With over 35 years of experience in the medical device sector, including leadership roles at LivaNova and Danaher, McDonald aims to lead Enovis into its next growth phase. Enovis has also announced the assumption of independent Chair of the Board by Sharon Wienbar following Trerotola's departure.
Read more →ENOVEnovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
Enovis™ is set to showcase its extensive range of foot and ankle solutions at the ACFAS Annual Scientific Conference in Phoenix, Arizona, from March 27-30, 2025. The company will highlight innovative products like the Tarsoplasty Percutaneous Lapidus Correction System and will emphasize its commitment to surgeon training and education. Enovis will also present new research on its Arsenal Foot™ Plating System. Additionally, the company will host engagements for industry experts to discuss innovations in foot and ankle surgery.
Read more →ENOVEnovis Announces Planned CEO Succession Process WILMINGTON, DE
Enovis Corporation announced a planned succession for its CEO, Matt Trerotola, who will retire upon the appointment of his successor by the Board of Directors. The company aims to select a leader focused on growth in the MedTech sector, maintaining its commitment to innovative solutions that enhance patient outcomes. Trerotola will assist during the transition as an Executive Advisor for one year, emphasizing the company's strong position in the market. Details regarding the leadership transition will be discussed in an upcoming financial results conference call.
Read more →ENOVEnovis Announces Planned CEO Succession Process
Enovis Corporation has announced the planned retirement of CEO Matt Trerotola, effective upon the appointment of his successor. The Board of Directors is collaborating with an executive search firm to find a leader who aligns with the company’s growth-oriented strategy. Trerotola will remain as an Executive Advisor for one year to facilitate a smooth transition. The Board is appreciative of Trerotola's contributions, noting the company's strong positioning and commitment to ongoing innovation.
Read more →ENOVEnovis Announces Fourth Quarter and Full Year 2024 Results
Enovis Corporation announced its financial results for Q4 and full year 2024, reporting significant growth in sales despite a substantial net loss. The fourth quarter saw sales increase by 23%, driven largely by a 59% rise in Reconstructive sales. Although the company faces challenges, including a significant goodwill impairment and leadership changes, it provided a positive outlook for 2025 with anticipated revenue growth. The announcement includes expectations for adjusted EBITDA improvements and strategic product launches planned for the coming year.
Read more →ENOVEnovis to Host Fourth Quarter and Full Year 2024 Results Conference Call on February 26th
Enovis Corporation announced it will host an investor conference call on February 26, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results. The company plans to issue an earnings press release earlier that same morning. Investors can access the call via a live webcast and a replay will be available on their website later in the day. Enovis emphasizes its innovation-driven approach, focusing on improvements in patient outcomes and orthopedic solutions.
Read more →ENOVEnovis™ Announces Leadership Change to International Surgical Business
Enovis™ has announced that Davide Visentin will take over as President of Enovis International Surgical effective March 1, 2025. Visentin, who has over 20 years of healthcare experience, previously worked at BD and Stryker, indicating a strong background in the medical technology field. The company expresses gratitude for the leadership of Dr. Benjamin Reinmann and emphasizes their commitment to further growth and innovation in the orthopedics sector. Enovis aims to improve patient outcomes with strategic advancements in their International Surgical Business.
Read more →ENOVEnovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Enovis Corporation (NYSE: ENOV) announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, set for January 13th, 2025. The company’s management will engage with investors during the event, highlighting its commitment to innovation in the medical technology sector. A live audio webcast and presentation materials will be accessible on the company's website, offering stakeholders insight into their developments and strategies.
Read more →ENOVForward-looking Statements This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking
Enovis presented forward-looking statements at the 2025 JP Morgan Healthcare Conference, highlighting its business outlook, goals, and the inherent risks involved. The company emphasized its strength in the reconstructive sector, aiming for growth above market averages, while also detailing its strategies for innovation and market expansion. However, uncertainties including public health emergencies and geopolitical tensions pose risks that could affect its future financial performance. Enovis assures that its results will align closely with consensus estimates for 2024, pending year-end accounting adjustments.
Read more →ENOVEnovis Announces Third Quarter 2024 Results
Enovis Corporation reported strong financial results for the third quarter of 2024, showcasing a 21% increase in net sales, largely driven by a significant 57% growth in Reconstructive sales. The company also demonstrated improvements in adjusted earnings per diluted share, which rose by 30% year-over-year. Despite these positive trends, Enovis reported a net loss of $34 million for the quarter. Additionally, the firm has narrowed its revenue and adjusted EBITDA expectations for the full year, raising its outlook for adjusted earnings per share.
Read more →ENOVEnovis to Host Third Quarter 2024 Results Conference Call on November 6th
Enovis Corporation announced it will host a conference call on November 6th, 2024, to discuss its third quarter financial results. The call is set for 8:30 a.m. Eastern Time, and attendees can participate via a webcast or by dialing in. Enovis emphasizes its dedication to innovation within medical technology, focusing on solutions that improve patient outcomes. The company encourages investors to stay updated through their dedicated Investor Relations website.
Read more →ENOVEnovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
Enovis has appointed Tim Czartoski as the President of U.S. Surgical and Global Product and Enabling Technologies. Czartoski brings over 22 years of experience from Depuy Synthes, where he held several leadership roles. His appointment is seen as a move to accelerate growth and strengthen the company's surgical product pipeline. Enovis aims to develop clinically differentiated solutions to improve patient outcomes and transform workflows in the orthopedic field.
Read more →ENOVEnovis™ Introduces the Next Generation of Foot and Ankle Surgery Offerings at AOFAS Annual Meeting
Enovis (NYSE: ENOV) will present its new Tarsoplasty Percutaneous Lapidus System and the Better Step platform at the AOFAS annual meeting from September 11-14, 2024. The Tarsoplasty System aims to enhance guided procedures and improve recovery for hallux valgus corrections. The Better Step platform provides personalized resources for patients during their recovery. These developments reflect Enovis's dedication to advancing patient care and surgical efficiency in the foot and ankle domain.
Read more →ENOVEnovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures
Enovis has expanded its EMPOWR Revision Knee system by adding EMPOWR Cones, which are designed to address bone defects and enhance revision knee surgeries. The updated system allows for a streamlined setup, reducing clutter and improving surgical workflow. Surgeons, including Dr. Leonard T. Buller and Dr. Beau J. Kildow, have reported positive experiences with the new cones, highlighting their fit and ease of use. The EMPOWR Revision Knee system aims to meet the growing demand for efficient outpatient revision procedures.
Read more →ENOVEnovis™ Introduces STAR Ankle, now with e+™ Polyethylene for Unmatched Durability
Enovis Corporation has launched its STAR Ankle equipped with e+ Polyethylene, following FDA approval. This new material promises unmatched durability and stability due to its vitamin E-blended composition. The STAR Ankle is noted to be the first mobile bearing ankle system utilizing this advanced polyethylene in the U.S. The company highlights continued commitment to enhancing patient outcomes and satisfaction through innovative technologies.
Read more →ENOVEnovis Announces Second Quarter 2024 Results
Enovis Corporation announced its financial results for the second quarter of 2024, highlighting a notable 23% growth in net sales, totaling $525 million. Although the company reported a net loss of $18 million, it demonstrated adjusted earnings of $0.62 per share and improved margins. The CEO expressed optimism regarding the integration of the recent Lima acquisition and upcoming product launches. Enovis reaffirmed its revenue expectations for the full year, indicating a positive outlook moving forward.
Read more →ENOVEnovis Announces Time Change for Second Quarter 2024 Results Conference Call
Enovis Corporation has announced a change in the timing of its second quarter 2024 earnings results conference call, moving it to 8:00 a.m. Eastern Time on August 7, 2024. The date remains unchanged, and all essential dial-in and webcasting information are still valid. This announcement reflects the company's ongoing commitment to keeping investors informed, as it routinely shares material information through various channels.
Read more →ENOVEnovis to Host Second Quarter 2024 Results Conference Call on August 7th
Enovis Corporation will host a conference call on August 7, 2024, to discuss its second quarter 2024 financial results. The call is scheduled for 8:30 a.m. Eastern Time, with a presentation to be made available on their investor relations website. Investors can participate via a live webcast or by dialing designated phone numbers. The company highlights its commitment to innovation and enhancing patient care.
Read more →ENOVEnovis™ Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse
Enovis has launched the AltiVate Reverse Glenoid System, a modular implant designed for reverse shoulder arthroplasty. It offers enhanced options for surgeons and aims to improve patient outcomes with its bone-sparing design and various baseplate configurations. The system received FDA approval earlier in May 2024 and was first used in surgery by Dr. Mark Frankle, a noted expert in shoulder procedures. This product aims to address the increasing demand for diverse shoulder replacement options as indications for reverse shoulder surgery expand.
Read more →ENOVEnovis Announces First Quarter 2024 Results
Enovis Corporation announced its financial results for the first quarter of 2024, revealing a 27% growth in net sales to $516 million compared to the same quarter in the previous year. Despite a net loss of $72 million and challenges linked to new acquisitions, the company reported improved adjusted EBITDA margins and positive growth in product lines. Enovis also updated its financial outlook for 2024, projecting higher revenue and adjusted earnings per share than previously anticipated. The results highlight ongoing growth and product innovation within the company.
Read more →ENOVEnovis to Host First Quarter 2024 Results Conference Call on May 2nd
Enovis Corporation, an innovation-driven medical technology company, announced it will host a conference call on May 2, 2024, to discuss its first quarter financial results. The call is set for 8:00 a.m. Eastern Time, with an earnings press release to be issued prior. Investors can access the live webcast through the Enovis website, and a replay will be available later that day. This initiative reflects Enovis's commitment to transparency and maintaining investor relations.
Read more →ENOVEnovis to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Enovis Corporation announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, scheduled for April 9, 2024. The Company will provide a live audio webcast of the presentation, focusing on its innovation-driven approach in medical technology. Enovis aims to showcase its commitment to developing solutions that enhance patient outcomes and transform healthcare workflows.
Read more →ENOVEnovis Announces Fourth Quarter and Full Year 2023 Results
Enovis Corporation announced its financial results for the fourth quarter and full year of 2023, showcasing a fourth-quarter sales growth of 11% and an adjusted EBITDA margin of 18%. The company reported a full-year net sales growth of 9% year over year, despite a net loss from continuing operations of $54 million. Enovis is set to enter 2024 with anticipated revenues of $2.05-2.15 billion, bolstered by the recent acquisition of LimaCorporate. CEO Matt Trerotola expressed confidence in the company's operational momentum and upcoming product introductions.
Read more →ENOVEnovis™ to Highlight Latest Technologies Across the Orthopedic Care Continuum at 2024 AAOS Annual Meeting
Enovis Corporation will showcase its latest orthopedic technologies at the 2024 AAOS Annual Meeting. The company has recently integrated LimaCorporate, enhancing its product offerings and capabilities. Enovis plans to launch a record number of new products in 2024, including advanced solutions for joint surgeries that aim to improve patient outcomes. Notable innovations include the ARVIS Augmented Reality system and the EMPOWR 3D Knee, which aligns with natural knee movement.
Read more →ENOVEnovis to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
Enovis Corporation has announced that key executives will present at the Canaccord Genuity Musculoskeletal Conference on February 12, 2024. This presentation will be led by President and COO Brady Shirley, CFO Ben Berry, and Group President Louis Vogt. A link to a live audio webcast and a replay will be available on the company's website. Enovis emphasizes its commitment to developing innovative medical technologies aimed at improving patient outcomes.
Read more →ENOVEnovis Showcases New Foot & Ankle Offerings at the ACFAS Annual Meeting
Enovis Corporation will present its latest foot and ankle products at the ACFAS annual meeting in Tampa, Florida, from February 1-4, 2024. The company will highlight technologies from its recent acquisitions, including Novastep® and their proprietary Evolve34™ Lapidus Correction System, which aims to improve patient outcomes. Enovis will also showcase several existing products and provide attendees with opportunities to experience their innovations firsthand. The event underscores the company's dedication to advancing medical technology in the field of orthopedics.
Read more →ENOVEnovis to Host Fourth Quarter and Full Year 2023 Conference Call on February 22nd
Enovis Corporation announced it will hold a conference call and live webcast on February 22, 2024, to discuss its fourth quarter and full year 2023 financial results. An earnings press release will be issued earlier that morning. Participants can join via a call or online link available on the company's website. Enovis aims to showcase its innovations and commitment to improved patient outcomes during the call.
Read more →ENOVEnovis Introduces the DonJoy ROAM™ OA Knee Brace
Enovis Corporation has launched the DonJoy ROAM OA knee brace, designed for patients suffering from osteoarthritis and other causes of knee pain. This brace utilizes advanced unloader technology to relieve pressure on the knee and improve mobility. It incorporates several user-friendly features, such as magnetic clips and adjustable support, catering to both conservative and postoperative care. The brace aims to provide effective pain relief while allowing users to maintain an active lifestyle.
Read more →ENOVEnovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America ("non-GAAP"). These non-GAAP financial
Enovis has provided non-GAAP financial information during a presentation at the 2024 JP Morgan Healthcare Conference, which highlights their adjusted net income metrics and EBITDA figures. The company is projecting over $2 billion in sales by 2024 and is optimistic about growth driven by the recent acquisition of LimaCorporate. However, Enovis acknowledged potential risks related to integration and various uncertainties affecting future performance. The presentation aimed to position Enovis as a leader in the MedTech market with a focus on innovation.
Read more →ENOVEnovis Completes Acquisition of LimaCorporate S.p.A
Enovis Corporation has successfully completed the acquisition of LimaCorporate S.p.A., enhancing its presence in the orthopedic reconstruction market. This strategic move aims to leverage Lima's innovative technologies, including 3D printed implants, to drive growth and improvement in patient outcomes. The acquisition brings Enovis' reconstructive segment revenues to $1 billion, indicating a strong market position. Additionally, the combined team is anticipated to propel Enovis into a faster growth trajectory within the industry.
Read more →ENOVEnovis Completes Acquisition of LimaCorporate S.p.A WILMINGTON, DE
Enovis Corporation has completed its acquisition of LimaCorporate S.p.A., strengthening its position in the global orthopedic reconstruction market. Lima brings a proven surgical solutions portfolio, including 3D printed Trabecular Titanium implants, enhancing Enovis' capabilities in the extremities market. This acquisition is expected to accelerate growth and increase revenue, bringing Enovis' reconstruction segment revenues to $1 billion. The integration of Lima's team is viewed as a strategic move to drive long-term value for shareholders.
Read more →ENOVEnovis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Enovis Corporation will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024. The event will feature a presentation by the management team aimed at investors, highlighting the company's innovations in medical technology. Enovis is known for its dedication to developing solutions that improve patient outcomes and streamline workflows in orthopedics and other fields. A live audio webcast of the event, along with a replay, will be available on the company’s website.
Read more →ENOVEnovis Announces Business Segment Leadership Transition Plan Brady R. Shirley, current President and COO, to retire effective
Enovis Corporation has announced the retirement of Brady R. Shirley, President and COO, effective Q1 2025, with his transition managed for continuity. He will become an Executive Advisor, focusing on the Lima acquisition integration. Louie Vogt and Terry Ross will be promoted to executive officers beginning January 2, 2024. The changes aim to ensure leadership stability while maintaining momentum in the company’s strategy and operations.
Read more →ENOVEnovis to participate in the 6th Annual EverCore ISI HealthCONx Conference
Enovis Corporation (NYSE: ENOV) will participate in the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. CEO Matt Trerotola and CFO Ben Berry will represent the company during their presentation. A webcast of this presentation will be made accessible on the Enovis website, allowing for wider investor interaction. The event reflects Enovis' commitment to showcasing its innovative medical technology solutions.
Read more →ENOVEnovis Announces Third Quarter 2023 Results and Raises Full-Year Outlook
Enovis Corporation reported strong third quarter 2023 results, with net sales growing 9% year-over-year to $418 million. The company improved its full-year outlook, expecting increased revenue and adjusted EBITDA, driven by growth in the Reconstructive and Prevention and Recovery segments. However, the company also reported a net loss of $19 million, raising concerns. The leadership highlighted a pending acquisition of LimaCorporate aimed at furthering growth and enhancing margins.
Read more →ENOVEnovis™ to Showcase New Surgical Innovations at AAHKS Annual Meeting
Enovis Corporation (NYSE: ENOV) announced its participation in the AAHKS Annual Meeting where it will present several new surgical innovations, including the updated ARVIS® Augmented Reality System and the EMPOWR™ blade stem. These technologies are designed to enhance surgical precision and efficiency, ultimately improving patient outcomes. Additionally, the EMPOWR 3D Knee® is highlighted as the only dual-pivot total knee available, further showcasing the company's commitment to advancing orthopedic solutions. Attendees can experience the innovations firsthand at booth #501 during the event in Grapevine, Texas, from November 2-5, 2023.
Read more →ENOVENOVIS CORPORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $400 MILLION OF 3.875% CONVERTIBLE SENIOR NOTES DUE 2028 WILMINGTON, DE
Enovis Corporation has announced the pricing of $400 million in 3.875% Convertible Senior Notes due 2028, showcasing robust demand. The offering includes an option for initial purchasers to buy an additional $60 million. Proceeds from the offering are primarily intended to finance the pending acquisition of LimaCorporate. However, the completion of this acquisition is critical for the success of the offering and the note conversion terms.
Read more →ENOVENOVIS CORPORATION ANNOUNCES PRICING OF PRIVATE OFFERING OF $400 MILLION OF 3.875% CONVERTIBLE SENIOR NOTES DUE 2028
Enovis Corporation has priced a private offering totaling $400 million in 3.875% Convertible Senior Notes due in 2028. The funds will primarily be used to finance the pending acquisition of LimaCorporate S.p.A. and cover costs associated with capped call transactions. The offering has garnered participation from qualified institutional buyers and is expected to close on October 24, 2023. However, the company may redeem the notes if the Lima Acquisition isn't completed by June 30, 2024.
Read more →ENOVKPMG S.p.A. Revisione e organizzazione contabile Piazza Salvemini, 20 35131 PADOVA PD Telefono +39 049 8249101 Email it-fmauditaly@kpmg.it PEC kpmgspa@pec.kpmg.it Independent auditors report To the board of directors of
KPMG S.p.A. has issued an independent audit report on the consolidated financial statements of Limacorporate S.p.A. for the year ended December 31, 2022. The audit confirms that the financial statements present a true and fair view of the group's financial position and performance based on International Financial Reporting Standards. However, the report highlights a significant loss and acknowledges corrections to prior errors regarding compliance with accounting standards. The financial statements are also prepared for inclusion in Enovis Corporation's offering memorandum.
Read more →ENOVEnovis Corporation Releases Preliminary Information About Its Performance for the Third Quarter 2023
Enovis Corporation has released preliminary financial results for Q3 2023, indicating expected revenues between $414 million and $418 million, up from approximately $383 million in Q3 2022. The company also anticipates an increase in adjusted EBITDA to between $64 million and $66 million, representing significant operational growth. However, these preliminary estimates are subject to change and have not been audited, reflecting a potential risk of inaccuracies. Management warned that various market and economic uncertainties could affect future performance.
Read more →ENOVEnovis Corporation Announces Proposed Private Offering of $400 Million of Convertible Senior Notes
Enovis Corporation announced a proposed private offering of $400 million in convertible senior notes due 2028. The offering may include an additional $60 million if initial purchasers exercise their option. The funds are intended to support the pending acquisition of LimaCorporate and to cover costs associated with capped call transactions. Enovis plans to utilize net proceeds for general corporate purposes if the acquisition does not complete by mid-2024, which indicates potential market risks.
Read more →ENOVEnovis to Host Third Quarter 2023 Results Conference Call on November 7th
Enovis Corporation has announced plans to host a conference call on November 7, 2023, to discuss its third quarter 2023 financial results. The call will take place at 8:00 a.m. Eastern Time and will be accessible through their website. Investors will also receive a press release earlier that day, indicating the company's dedication to transparency in communicating financial performance.
Read more →ENOVEnovis to Acquire LimaCorporate S.p.A. Creating a high-growth, global reconstruction leader with ~$1 billion in annual revenue Attractive margin profile and meaningful synergies expected to increase profitability WILMING
Enovis Corporation has announced an agreement to acquire LimaCorporate S.p.A. for approximately $800 million, which includes $700 million in cash and $100 million in Enovis stock. This acquisition is expected to bolster Enovis's growth in the orthopedic market by providing complementary products and significant synergies. Lima, known for its advanced orthopedic implant solutions, is projected to generate substantial revenues and EBITDA in 2024. The deal is anticipated to close in early 2024, pending regulatory approvals.
Read more →ENOVEnovis to Acquire LimaCorporate S.p.A.
Enovis Corporation has entered into a definitive agreement to acquire LimaCorporate S.p.A. for approximately €800 million. The acquisition is aimed at establishing a leading global reconstruction business, projected to generate around $1 billion in revenue. Lima, known for its innovative orthopedic solutions, is expected to provide strategic benefits, including cost synergies and enhanced product offerings. However, the deal is subject to regulatory approvals and poses certain financial uncertainties.
Read more →ENOVEnovis Debuts New Foot & Ankle Offerings at the AOFAS Annual Meeting
Enovis Corporation (NYSE: ENOV) is set to debut new foot and ankle products at the AOFAS Annual Meeting in Louisville, Kentucky, from September 20-23, 2023. Highlights include offerings from the recent acquisitions of Novastep® and D.N.E., LLC, as well as the new Evolve34™ Lapidus Instrumentation. The company aims to enhance patient outcomes with these innovative technologies designed for various foot and ankle conditions. Enovis will also showcase several additional products to improve surgical efficiency during the conference.
Read more →ENOVMatt Trerotola Chief Executive Officer Ben Berry Chief Financial Officer Forward-looking Statements Non-GAAP Financial Information This presentation includes forward-looking statements, including Enovis has provided in t
Enovis provided a presentation outlining its forward-looking statements and financial guidance for 2023, emphasizing its strategic goals for revenue and aEBITDA. The company expects to achieve high single-digit growth, targeting over $2 billion in sales by 2024 while highlighting significant market opportunities within the Orthopedic sector. However, risks associated with geopolitical tensions, supply chain issues, and the ongoing effects of the COVID-19 pandemic could impact their financial performance. Enovis also discussed its unique positioning in the market, strengthened through both organic and inorganic growth strategies.
Read more →ENOVEnovis Announces Second Quarter 2023 Results and Raises Full-Year Outlook
Enovis Corporation announced strong financial results for the second quarter of 2023, reporting an 8% increase in net sales year-over-year, alongside organic growth in its Recon and Prevention segments. Despite a net loss from continuing operations of $15 million, the company saw an improvement in adjusted EBITDA and raised its financial outlook for the year. The CEO expressed optimism about maintaining operational momentum and the impact of strategic initiatives, while acknowledging potential risks related to economic conditions and geopolitical tensions.
Read more →ENOVEnovis to Host Second Quarter 2023 Results Conference Call on August 3rd
Enovis Corporation announced it will hold an investor conference call on August 3, 2023, at 8:30 a.m. Eastern Time to discuss its second quarter 2023 financial results. A press release will be issued earlier that day, and a related presentation will be available on their website. The call aims to provide insights into the company's performance and future strategies.
Read more →ENOVEnovis™ Recognized as One of America’s Greatest Workplaces 2023 by Newsweek
Enovis Corporation has been honored as one of America’s Greatest Workplaces 2023 according to Newsweek. This recognition was made possible through a comprehensive employer study that analyzed over 389,000 company reviews across the United States. Enovis emphasizes a positive work environment and is committed to fostering diversity and inclusion among its workforce. The award underlines the company's efforts to improve patient outcomes while creating a collaborative culture.
Read more →ENOVEnovis™ Completes Acquisition of Novastep
Enovis Corporation has completed the acquisition of Novastep, a subsidiary of Amplitude Surgical SA, which focuses on developing foot and ankle solutions. This acquisition is expected to strengthen Enovis' position in the bunion market through Novastep's innovative MIS bunion system, Pecaplasty. The move will also support Enovis' international growth strategy, providing access to Novastep’s CE marked implants. Enovis expresses enthusiasm about collaborating with Novastep’s team to advance healthcare solutions.
Read more →ENOVEnovis to Participate in Investor Conferences in June
Enovis Corporation has announced its participation in several key investor conferences in June 2023. The Chief Financial Officer, Ben Berry, will represent the company at the Jefferies Healthcare Conference and the JMP Securities Mid-Year MedTech Forum. Additionally, the Chief Executive Officer, Matt Trerotola, will join Berry at the Goldman Sachs 44th Annual Global Healthcare Conference. This engagement highlights Enovis's commitment to innovation in the medical technology sector.
Read more →ENOVEnovis Announces First Quarter 2023 Results
Enovis Corporation reported positive financial results for the first quarter of 2023, showing an 8% increase in net sales and a 9% organic growth. The company indicated strong performance in its Reconstructive segment, achieving 19% organic growth. Despite these gains, Enovis also reported a net loss of $23 million for the quarter. The company has revised its financial outlook for the year, projecting higher revenue growth and adjusted EBITDA compared to previous estimates. Enovis continues to focus on innovation and acquisition opportunities to enhance its market position.
Read more →ENOVEnovis to Host First Quarter 2023 Results Conference Call on May 4th
Enovis Corporation has announced that it will host a conference call on May 4, 2023, to discuss its financial results for the first quarter of 2023. The call will be accessible to investors via a live webcast and a replay will be made available afterward. This event underscores the company's commitment to transparency and engagement with its investors while providing insights into its growth trajectory in the medical technology sector.
Read more →ENOVEnovis to Acquire Novastep
Enovis Corporation has announced a definitive agreement to acquire Novastep, a leading developer of minimally invasive foot and ankle solutions. With around $20 million in annual revenues, Novastep is noted for its innovative PECAPLASTY bunion system. The acquisition aims to strengthen Enovis’ position in the global foot and ankle market and accelerate its international strategy. The completion of the transaction is subject to customary closing conditions and regulatory approvals, expected to close in the second quarter of 2023.
Read more →ENOVEnovis Announces Board Leadership Transition CEO Matt Trerotola to be named Chair and Director Sharon Wienbar to become Lead Independent Director following retirement of current Chair Mitchell P. Rales at 2023 Annual Mee
Enovis Corporation announced a significant leadership transition where CEO Matt Trerotola will become Chair of the Board following the retirement of current Chair Mitchell P. Rales. This change will take effect after the 2023 Annual Meeting of Stockholders. Alongside Trerotola's new role, Sharon Wienbar will assume the position of Lead Independent Director, marking a progressive step in the company's governance. Both Trerotola and Wienbar expressed appreciation for Rales's contributions and confidence in Enovis's continued growth and innovation.
Read more →ENOVEnovis Announces Board Leadership Transition
Enovis Corporation has announced a leadership transition, with CEO Matt Trerotola taking on the role of Chair of the Board effective May 16, 2023. This change comes as current Chair Mitchell P. Rales retires and will not seek re-election. Trerotola emphasizes the company's commitment to sustainable growth and innovation. Sharon Wienbar will become Lead Independent Director, signaling a strong governance structure moving forward.
Read more →ENOVENOVIS™ Showcases Next Generation of Medical Technology at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting
Enovis Corporation (ENOV) announced its participation in the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, where it will showcase next-generation medical technology highlighting its innovative products and collaborations. The company is launching the 'Better Is' campaign to emphasize its partnerships in advancing orthopedic solutions. Key products included are the EMPOWR Revision Knee™ and AltiVate® Anatomic Augmented Glenoid System, along with software like the OaraScore® for outpatient risk assessment. Enovis aims to enhance surgical efficiency and improve patient outcomes through continuous innovation and collaboration.
Read more →ENOVEnovis Announces Fourth Quarter and Full Year 2022 Results
Enovis Corporation (NYSE: ENOV) announced its financial results for the fourth quarter and fiscal year 2022, highlighting a 10% growth in net sales for the year. The Reconstructive segment performed particularly well with a 12% increase in sales, despite the Prevention and Recovery segment reporting a decline. The company also faced operating losses during the fourth quarter, amounting to $28 million. Looking ahead, Enovis forecasts 5-6% organic growth for 2023 and aims to increase its adjusted EBITDA significantly.
Read more →ENOVEnovis to Host Fourth Quarter and Full Year 2022 Conference Call on February 23rd
Enovis Corporation, a medical technology company, has announced it will host an investor conference call on February 23, 2023, at 8:30 AM ET. The purpose of the call is to discuss the financial results for the fourth quarter and full year of 2022. An earnings press release will be issued earlier that same morning, and a presentation will be made available on their website. Investors can participate via a live webcast or by phone.
Read more →ENOVEnovis™ to Showcase Latest Innovations and Growing Foot & Ankle Portfolio at ACFAS 2023
Enovis Corporation will present its expanding Foot & Ankle offerings at the ACFAS 2023 conference in Los Angeles from February 9-12, 2023. The company aims to highlight its innovative products, including the DynaNail Helix and various bone staples, emphasizing their commitment to improving patient outcomes. Enovis also invites attendees to participate in an industry session focused on new product innovation, further establishing its presence in the podiatric community.
Read more →ENOVEnovis Expands Foot & Ankle Portfolio’s DynaClip Family by Introducing Procedure-Specific Staples
Enovis Corporation has announced the launch of two new bone staples, the DynaClip Delta and DynaClip Quattro, enhancing their foot and ankle portfolio. These staples are designed for quick deployment and improved procedural efficiency, with data indicating their superior performance compared to traditional systems. Surgeons have reported positive outcomes with the new NiTiNOL technology, which offers sustained dynamic compression across fusion sites. This innovation aligns with Enovis's commitment to providing cutting-edge solutions for improved patient care.
Read more →ENOVEnovis to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Enovis Corporation has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference, with a scheduled presentation on January 9, 2023. The event will feature the company's management team meeting with investors, which provides an opportunity to showcase their innovative medical technology solutions. The conference represents an important platform for Enovis to highlight its commitment to improving patient outcomes and transforming healthcare workflows. A link to the live audio webcast of the presentation will be available on the company's website.
Read more →ENOVEnovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle
Wilmington, DE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that the U.S. Food and Drug Administration (FDA) has approved the STAR Patient Specific Instrumentation (STAR PSI System) for use with the
Read more →ENOVEnovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions
Wilmington, DE, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announces the introduction of the DynaNail Helix™, the latest addition to the DynaNail® family and Enovis’ expansive suite of foot and ankle product
Read more →ENOVEnovis’ ARVIS Awarded the AAHKS Industry Innovation Award at the 2022 American Academy of Hip and Knee Surgeons Annual Meeting
Wilmington, DE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced that the company’s ARVIS® Augmented Reality Surgical Guidance System received the Industry Innovation Award at the this year’s Amer
Read more →ENOVEnovis Announces Third Quarter 2022 Results
Grew sales to $384 million, including 7% organic growth over the prior year quarter, with double-digit growth performance across its Reconstructive segment Reported a net loss of $(1.22) per diluted share from continuing operations and increased its adjusted earnings per share 3
Read more →ENOVEnovis to Participate in Investor Conferences in November
Wilmington, DE, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in two investor conferences in November. On Tuesday, November 8, Chris Hix, CFO, and Ben Berry, i
Read more →ENOVEnovis to Host Third Quarter 2022 Conference Call on November 2nd
Wilmington, DE, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2022 financial results on Wednesday,
Read more →ENOVEnovis to Showcase New 510(k) Cleared Foot & Ankle Products at the AOFAS Annual Meeting
Wilmington, DE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Today, Enovis Corporation (NYSE: ENOV), an innovation-driven, medical technology company, announced it will showcase its foot & ankle continuum of care portfolio at the American Orthopaedic Foot & Ankle Society® (AOFAS) annual me
Read more →ENOVEnovis to Participate in Investor Conferences in September
Wilmington, DE, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences in September. 2022 Wells Fargo Healthcare
Read more →ENOVEnovis Announces Second Quarter 2022 Results
Sales of $395 million include 11% reported growth, 3% organic growth and 5% sales-per-day growth Reported operating income of $6 million, while adjusted EBITDA increased 11% to $56 million Reported earnings per diluted share from continuing operations of $2.21; expanded adjuste
Read more →ENOVEnovis to Host Second Quarter 2022 Conference Call on August 4th
Wilmington, DE, July 12, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2022 financial results on Thursday,
Read more →ENOVEnovis Completes Acquisition of Insight Medical Systems
WILMINGTON, DE, July 06, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, announced that it has acquired Insight Medical Systems, a technology company dedicated to reimagining orthopedic surgical guidance. Insight’
Read more →ENOVEnovis Announces Chief Financial Officer Transition Plan Wilmington, Delaware
Enovis Announces Chief Financial Officer Transition Plan Wilmington, Delaware, June 30, 2022 Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that Ben Berry, CFO of the Company s business units, will succeed Chris Hix as C
Read more →ENOVEnovis to Participate in the Goldman Sachs Global Healthcare Conference
Wilmington, DE, June 06, 2022 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13, 2022
Read more →ENOVEnovis Announces First Quarter 2022 Adjusted Stand-Alone Results Increased stand-alone sales 21% to $375 million; organic growth of 7% Grew adjusted stand-alone EBITDA 25% to $48 million Achieved adjusted stand-alone ear
Enovis Announces First Quarter 2022 Adjusted Stand-Alone Results WILMINGTON, DE, May 10, 2022 (GLOBE NEWSWIRE) Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced its adjusted stand-alone
Read more →ENOVEnovis Schedules First Quarter 2022 Earnings Release and Conference Call
Wilmington, DE, April 14, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced that it will issue a press release on the morning of Tuesday, May 10, 2022 providing pr
Read more →ENOVEnovis (formerly Colfax) Completes Spin-off of ESAB Corporation WILMINGTON, DE
Enovis (formerly Colfax) Completes Spin-off of ESAB Corporation WILMINGTON, DE, April 5, 2022 (GLOBE NEWSWIRE) Enovis Corporation ( Enovis or the Company ) (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, announced today
Read more →ENOVColfax Announces Expected Completion Date of
Colfax Announces Expected Completion Date of April 4, 2022 for Spin-Off of ESAB Corporation WILMINGTON, DE, March 14, 2022 (GLOBE NEWSWIRE) Colfax Corporation ( Colfax ) (NYSE: CFX) today announced that its Board of Directors has declared (a) a pro rata distribution of 90% of
Read more →ENOVForward Looking Statement and Non-GAAP Disclaimer This document has been prepared by Colfax Corporation, a Delaware corporation ("Colfax"), solely for informational purposes. Upon completion of the intended separation of
March 14, 2022 Investor Presentation Enovis: An Innovation Driven Medical Technology Company Exhibit 99.1 Forward Looking Statement and Non-GAAP Disclaimer This document has been prepared by Colfax Corporation, a Delaware corporation ("Colfax"), solely for informational purpos
Read more →ENOVColfax Announces Board of Directors for Enovis, the Post-Spinoff Medical Technology Company WILMINGTON, DE
Colfax Announces Board of Directors for Enovis, the Post-Spinoff Medical WILMINGTON, DE, March 11, 2022 (GLOBE NEWSWIRE) Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced the future composition of the Board of Directors (the Board ) of th
Read more →ENOVEXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT ( Agreement ) is entered into as of the 21st day of February, 2022, by and among ESAB Corporation, a Delaware corporation (the Company ) and Shyam Kambeyanda, an i
EXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT ( Agreement ) is entered into as of the 21st day of February, 2022, by and among ESAB Corporation, a Delaware corporation (the Company ) and Shyam Kambeyanda, an individual (the Executive ). the Company desires to employ
Read more →ENOVColfax Announces Plans for Reverse Stock Split WILMINGTON, DE
Colfax Announces Plans for Reverse Stock Split WILMINGTON, DE, December 30, 2021 (GLOBE NEWSWIRE) Colfax Corporation ( Colfax or the Company ) (NYSE: CFX), a leading diversified technology company, announced today that it plans to hold a special meeting of stockholders to seek
Read more →ENOVColfax Corporation Investor Day
Colfax Corporation Investor Day March 11, 2021 Forward Looking Statement & Non-GAAP Disclaimer These materials include "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be characterized by ter
Read more →ENOVCOLFAX ANNOUNCES INTENTION TO SEPARATE INTO TWO INDEPENDENT PUBLIC COMPANIES Will Create Focused Specialty Medical Technology and Fabrication Technology Companies Separation Will Accelerate Strategic Momentum and Unlock
COLFAX ANNOUNCES INTENTION TO SEPARATE INTO TWO INDEPENDENT PUBLIC COMPANIES Will Create Focused Specialty Medical Technology and Fabrication Technology Companies Separation Will Accelerate Strategic Momentum and Unlock Significant Value Creation Potential Company Intends Tax
Read more →ENOVPhilip Okala Appointed to Colfax Board of Directors Annapolis Junction, MD
Philip Okala Appointed to Colfax Board of Directors Annapolis Junction, MD, February 22, 2021 Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it has appointed Philip Okala, Chief Operating Officer of the University of Pennsylvania
Read more →ENOVInvestor Day December 2019 Forward Looking Statements & Non-GAAP Disclaimer The following information may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Se
Forward Looking Statements & Non-GAAP Disclaimer The following information may contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but a
Read more →ENOVLiam Kelly Appointed to Colfax Board of Directors Annapolis Junction, MD
Liam Kelly Appointed to Colfax Board of Directors Annapolis Junction, MD, December 11, 2019 Colfax Corporation (NYSE: CFX), a leading global manufacturer of medical technology and fabrication technology products and services, today announced that it has appointed Liam Kelly, Pr
Read more →ENOVColfax Announces Agreement to Sell Its Air and Gas Handling Business to KPS Capital Partners for Enterprise Value of $1.8 Billion
Colfax Announces Agreement to Sell Its Air and Gas Handling Business to KPS Capital Partners for Enterprise Value of Annapolis Junction, MD, May 16, 2019 (GLOBE NEWSWIRE) Colfax Corporation ( Colfax ) (NYSE: CFX), a leading diversified technology company, announced that it has
Read more →ENOVColfax Completes Acquisition of DJO Global, Inc., Schedules 2019 Outlook Conference Call Annapolis Junction, MD , 25 February 2019 Colfax Corporation ( Colfax ) (NYSE: CFX), a leading diversified technology company, anno
Colfax Completes Acquisition of DJO Global, Inc., Schedules 2019 Outlook Conference Call Annapolis Junction, MD, 25 February 2019 Colfax Corporation ( Colfax ) (NYSE: CFX), a leading diversified technology company, announced that it has completed the previously announced acquis
Read more →ENOVColfax Announces Pricing of 6.000% Senior Notes due 2024 and 6.375% Senior Notes due 2026
Colfax Announces Pricing of 6.000% Senior Notes due 2024 and 6.375% Senior Notes due 2026 ANNAPOLIS JUNCTION, MD January 31, 2019 Colfax Corporation (NYSE: CFX) ( Colfax ), a leading diversified technology company, today announced the pricing of $600 million aggregate principal
Read more →ENOVColfax Announces Offering of Senior Notes
Colfax Announces Offering of Senior Notes ANNAPOLIS JUNCTION, MD January 28, 2019 Colfax Corporation (NYSE: CFX) ( Colfax ), a leading diversified technology company, today announced the offering of two tranches of senior notes maturing in 2024 and 2026 to be issued by CFX Escr
Read more →ENOVSupplemental financial and operating information regarding the Company and DJO dated
Supplemental financial and operating information regarding the Company and DJO dated January 28, 2019 The supplemental financial and operating information regarding Colfax Corporation (which may be referred to herein as Colfax, the Company, we, our and us ) and DJO Global, Inc.
Read more →ENOVErnst & Young LLP Tel: +1 858 535 7200 Suite 1600 Fax: +1 858 535 7777 4365 Executive Drive ey.com San Diego, CA 92121 Report of Independent Auditors To the Board of Directors of DJO Global, Inc. We have audited the acco
Ernst & Young LLP Tel: +1 858 535 7200 Suite 1600 Fax: +1 858 535 7777 4365 Executive Drive ey.com San Diego, CA 92121 Report of Independent Auditors To the Board of Directors of DJO Global, Inc. the accompanying consolidated financial statements of DJO Globa
Read more →ENOVEXECUTION COPY CREDIT AGREEMENT dated as of
Table of Contents The Other Loan Parties Party Hereto The Lenders Party Hereto JPMORGAN CHASE BANK, N.A. Administrative Agent CREDIT SUISSE LOAN FUNDING LLC as Syndication Agent BANK, N.A., BNP PARIBAS, BARCLAYS BANK PLC, HSBC BANK USA, NATIONAL ASSOCIATION, GOLDMAN SACHS
Read more →ENOVColfax to Acquire DJO Global for $3.15 Billion in Cash DJO is Global Orthopedics Leader Strongly Positioned to Benefit from Macro Trends in $21 Billion Market Addition of Higher Margin, Faster Growth, and Less Cyclical B
Colfax to Acquire DJO Global for $3.15 Billion in Cash DJO is Global Orthopedics Leader Strongly Positioned to Benefit from Macro Trends in $21 Billion Market Addition of Higher Margin, Faster Growth, and Less Cyclical Business Significantly Shifts Colfax Portfolio, Consisten
Read more →ENOVColfax Completes Sale of Fluid Handling Business Annapolis Junction, MD (
Colfax Completes Sale of Fluid Handling Business Annapolis Junction, MD (December 11, 2017) -- Colfax Corporation ("Colfax") (NYSE: CFX), a leading diversified industrial technology company, today announced it completed the sale of its Fluid Handling business to CIRCOR Internati
Read more →ENOVINVESTOR DAY | NOVEMBER 2017 2 Forward-looking Statements These slides and accompanying oral presentation contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Se
INVESTOR DAY | NOVEMBER 2017 2 Forward-looking Statements These slides and accompanying oral presentation contain forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-lookin
Read more →ENOVColfax Announces Sale of Its Fluid Handling Business to CIRCOR Annapolis Junction, MD (
Colfax Announces Sale of Its Fluid Handling Business to CIRCOR Annapolis Junction, MD (September 25, 2017) -- Colfax Corporation ("Colfax") (NYSE: CFX), a leading diversified industrial technology company, today announced that it has signed a definitive agreement to sell its Flu
Read more →ENOVDidier Teirlinck Appointed to Colfax Board of Directors
Didier Teirlinck Appointed to Colfax Board of Directors ANNAPOLIS JUNCTION, MD September 19, 2017 Colfax Corporation (NYSE: CFX), a leading global manufacturer of gas and fluid-handling and fabrication technology products and services, today announced that it has appointed Didi
Read more →ENOVColfax Announces Pricing of 3.250% Senior Notes due 2025
Colfax Announces Pricing of 3.250% Senior Notes due 2025 ANNAPOLIS JUNCTION, MD April 12, 2017 Colfax Corporation (NYSE: CFX) ( Colfax ), a leading global manufacturer of gas and fluid-handling and fabrication technology products and services, today announced that it has priced
Read more →ENOVColfax Announces Offering of Senior Notes and Preliminary Trends for the First Quarter of 2017
Colfax Announces Offering of Senior Notes and Preliminary Trends for the First Quarter of 2017 ANNAPOLIS JUNCTION, MD April 7, 2017 Colfax Corporation (NYSE: CFX) ( Colfax ), a leading global manufacturer of gas and fluid-handling and fabrication technology products and service
Read more →ENOVColfax Names Shyam Kambeyanda as President, ESAB
Colfax Names Shyam Kambeyanda as President, ESAB ANNAPOLIS JUNCTION, MD - April 18, 2016 - Colfax Corporation (NYSE: CFX), a leading global manufacturer of gas and fluid-handling and fabrication technology products and services, today announced that Shyam Kambeyanda, formerly Pr
Read more →ENOVColfax Announces Clay Kiefaber to Retire as CEO of ESAB Business
Colfax Announces Clay Kiefaber to Retire as CEO of ESAB Business Colfax CEO Matthew Trerotola to Serve As Interim President at ESAB ANNAPOLIS JUNCTION, MD - November 17, 2015 - Colfax Corporation (NYSE: CFX), a leading global manufacturer of gas and fluid-handling and fabricati
Read more →Competitive Position
How ENOV ranks across every disease it competes inCompetitive Position is a premium feature
See how ENOV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial